

Frontiers in Anti-Infective Drug Discovery



Editors:

Atta-ur-Rahman, *FRS*

M. Iqbal Choudhary



Bentham Books

**Frontiers in Anti-Infective Drug
Discovery
(Volume 9)**

Edited By

Atta-ur-Rahman, *FRS*

*Kings College,
University of Cambridge,
Cambridge,
UK*

&

M. Iqbal Chaudhary

*H.E.J. Research Institute of Chemistry,
International Center for Chemical and Biological Sciences,
University of Karachi,
Karachi,
Pakistan*

Frontiers in Anti-Infective Drug Discovery

Volume # 9

Editor: Prof. Atta-ur-Rahman, *FRS* and M. Iqbal Chaudhary

ISSN (Online): 1879-663X

ISSN (Print): 2451-9162

ISBN (Online): 978-1-68108-829-7

ISBN (Print): 978-1-68108-830-3

ISBN (Paperback): 978-1-68108-831-0

©2021, Bentham eBooks imprint.

Published by Bentham Science Publishers Pte. Ltd. Sharjah. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 USE OF PRECLINICAL AND EARLY CLINICAL DATA FOR ACCELERATING ANTIMICROBIAL DRUG DEVELOPMENT	1
<i>Mahesh N. Samtani, Amarnath Sharma and Partha Nandy</i>	
INTRODUCTION	2
Drug, Bug and Host Interactions: Five Critical Factors	3
METHODOLOGICAL ASPECTS	6
Model for <i>In-vitro</i> MIC Distributions and Pathogen Frequency of Natural Occurrence	7
Model for <i>Ip/xkq</i> PK/PD Target	7
Population PK Parameters Representing Human Variability	8
Target Attainment Computation	9
Assumptions Adopted During Modelling And Simulation	12
CASE-STUDY RESULTS: APPLICATION OF MONTE-CARLO APPROACH	13
Target Indication and Patterns of <i>In-vitro</i> Killing	13
Pathogen Susceptibility and Natural Occurrence	13
PK/PD Target Based on The Murine Thigh Infection Model	14
Clinical PK	15
Monte Carlo Simulation Results	15
SUMMARY	16
CONSENT FOR PUBLICATION	19
CONFLICT OF INTEREST	19
ACKNOWLEDGEMENTS	19
APPENDIX 1A	19
APPENDIX 1B	20
REFERENCES	22
CHAPTER 2 POST-TRANSLATIONAL MODIFICATIONS: HOST DEFENCE MECHANISM, PATHOGENIC WEAPON, AND EMERGED TARGET OF ANTI-INFECTIVE DRUGS	25
<i>Maria Amprazi, Anastasia Tomatsidou, Dimitra Paliogianni and Vasiliki E. Fadouloglou</i>	
INTRODUCTION	26
PTMS IN THE FRONTLINE OF EUKARYOTIC DEFENCE AND PATHOGENIC INVASION	29
Innate Immunity	30
Adaptive Immunity: Antibodies	32
Eukaryotic Regulatory Processes Are Pathogenic Targets	33
BACTERIAL PATHOGENICITY EMPOWERED BY PTMS	34
Yersinia Yops Effectors: An Arsenal of Post-Translational Modifiers	35
Activation of Bacterial Effectors by Host-Mediated Post-Translational Modifications	39
Localization of Bacterial Effectors to Membranes by Host-Mediated Post Translational Lipidations	42
Eliminylation: A Particular Case of Dephosphorylation	45
AMPylation: An Emerging Modification in Bacterial Pathogenicity	46
ADP-Ribosylation: An Ancient Modification with Huge Potential for Infection	46
Deamidation: From Biological Clock to Virulence Factor	47
Bacterial Deamidation of Host G Proteins	47
Bacterial Deamidation of Transcription Factors Pauses Host Protein Synthesis	48

Bacterial Deamidation Targets the Ubiquitin/Ubiquitin-Like Protein Signaling Pathways ...	48
Bacterial Infection Interferes with the Canonical Ubiquitination	50
Bacterial Proteins Modify and Disrupt the Host Ubiquitination Network	50
Bacterial Proteins Are Modified by the Host Ubiquitination Network	52
Bacteria have Evolved Non-Canonical Ubiquitinases and Deubiquitinases	52
Phosphoribosyl Ubiquitinases and Deubiquitinases	52
Ubiquitin Transglutaminases	53
THE MULTIPLE FACETS OF GLYCOSYLATION IN BACTERIAL PATHOGENICITY	54
O-Glycosylation of Bacterial Flagella	55
N-Glycosylation of Bacterial Surface Proteins	58
O-Glycosylation of Host Proteins by Bacterial Toxins	58
N-Glycosylation of Host Proteins by Bacterial Effectors	61
VIRAL PATHOGENICITY THROUGH PTMS	62
Coronavirus (CoV) Family	62
PTMS FOUND IN CORONAVIRUS PROTEINS	65
Glycosylation	65
Disulfide Bond Formation	68
Palmitoylation	68
Phosphorylation	69
Ubiquitination	69
How Coronaviruses Induce PTMs to Host Proteins	69
THE POTENTIAL OF PTMS IN THE NEW ERA OF BIOPHARMACEUTICALS, ANTIBIOTICS AND ANTIVIRALS	70
The Challenge of Engineering PTMs in Biopharmaceuticals	70
Potential Anti-Viral Drugs	72
Promising Antimicrobial Targets	73
PTMS IN NATURAL ANTIMICROBIAL PEPTIDES AID SEARCH FOR NOVEL THERAPEUTICS	76
Lasso Peptides	77
Thiopeptides	80
Lanthipeptides/lantibiotics	82
Class I lantibiotics	82
Class II Lantibiotics	83
Class III and IV Lantibiotics	84
CONCLUSION AND FUTURE PERSPECTIVES	84
CONSENT FOR PUBLICATION	87
CONFLICT OF INTEREST	87
ACKNOWLEDGEMENTS	87
REFERENCES	87
CHAPTER 3 SCOPE AND LIMITATIONS ON THE POTENT ANTIMICROBIAL ACTIVITIES OF HYDRAZONE DERIVATIVES	123
<i>Jean Michel Brunel</i>	
INTRODUCTION	123
Hydrazones as Potent Antimicrobial Agents	125
R is a Hydrogen	125
R is an Aryl Group	126
R is a Heterocyclic Ring	128
Sulfonylhydrazones	138
Ylidene Hydrazone Derivatives	140
CONCLUDING REMARKS	150

CONSENT FOR PUBLICATION	150
CONFLICT OF INTEREST	151
ACKNOWLEDGEMENTS	151
REFERENCES	151
CHAPTER 4 CURRENT SCENARIO OF ANTI-LEISHMANIAL DRUGS AND TREATMENT	156
<i>Priyanka H. Mazire and Amit Roy</i>	
INTRODUCTION	156
History of Leishmaniasis	158
Morphology of Leishmania Parasites	160
Lifecycle of Leishmania Parasite	161
Classification of Leishmaniasis	162
Clinical Symptoms	164
Diagnosis of Leishmaniasis	165
Diagnosis of Cutaneous and Mucocutaneous leishmaniasis	165
Treatment for Leishmaniasis	167
CURRENTLY USED ANTI-LEISHMANIAL DRUGS	169
Amphotericin B	170
<i>Mechanism of Action</i>	172
<i>Treatment Regimen</i>	173
Miltefosine	173
<i>Mechanism of Action</i>	174
<i>Treatment Regimen</i>	174
Paromomycin (PM)	174
<i>Mechanism of Action</i>	175
<i>Treatment Regimen</i>	175
Pentavalent Antimonials (SbV)	175
<i>Mechanism of Action</i>	176
<i>Treatment Regimen</i>	176
Pentamidine	176
<i>Mechanism of Action</i>	176
<i>Treatment Regimen</i>	177
<i>Anti-leishmanial Activity of Compounds from Natural Sources</i>	177
Plants	177
Marine Macroalgae	178
Endophytes	179
CONCLUSION	180
CONSENT FOR PUBLICATION	180
CONFLICT OF INTEREST	180
ACKNOWLEDGEMENTS	180
REFERENCES	180
CHAPTER 5 DENGUE HEMORRHAGIC FEVER: THE POTENTIAL REPURPOSING DRUGS	187
<i>Wattana Leowattana, Pathomthep Leowattana and Tawitthep Leowattana</i>	
INTRODUCTION	187
DENV REPLICATION	188
DRUG REPURPOSING FOR DENGUE	190
RdRp Inhibitors	190
<i>Balapiravir</i>	190
<i>Sofosbuvir</i>	191
<i>Ribavirin</i>	191

Antibiotic	192
<i>Doxycycline</i>	192
Iminosugars	193
Celgosivir	193
<i>UV-4B</i>	194
Anti-parasitic drugs	196
<i>Chloroquine (CQ)</i>	196
Ivermectin	197
Mast Cell Stabilizers	198
<i>Cromolyn and Ketotifen</i>	198
Leukotriene Inhibitor and Platelet-activating Factor (PAF) Inhibitor	199
<i>Montelukast and Rupatadine</i>	199
CONCLUDING REMARKS	201
CONSENT FOR PUBLICATION	201
CONFLICT OF INTEREST	201
ACKNOWLEDGEMENTS	201
REFERENCES	201
SUBJECT INDEX	22:

PREFACE

Infections caused by viruses, bacteria, fungi, and parasites have caused death and suffering to humans and other life forms since their existence. Discoveries of antibiotics in 1928 and the development of vaccines were two important landmarks in our fight against harm caused by these unseen enemies. However, various infection-causing agents soon developed resistance against almost all available antibiotics, making the treatment an ever-growing challenge. Similarly, many fast mutating viruses have rendered many vaccines ineffective. The COVID-19 pandemic has posed an extensional threat to the human race, and it is a stark reminder of our vulnerabilities against infections. To meet these re-emerging challenges, it is imperative to constantly understand the molecular basis of infections and drug resistance, identify new drug targets and develop new chemotherapeutic agents. Unfortunately, till recently, pharmaceutical research for anti-infective agents has been given a low priority due to “economic feasibility” considerations. Only in the last decade, the topic has received global attention and vigorous research pursued in academic and pharmaceutical laboratories.

The book series “*Frontiers in Anti-infective Drug Discovery*” has been publishing review articles on key aspects of this field. Volume 9 is not different from the previous well-received volumes. It contains 5 carefully selected reviews on various key stages of drug development and approaches against infections caused by bacteria and parasites. The Review by Samatani *et al* is focused on a critically important aspect of drug development *i.e.* optimal choice of dose regimen. They explain the use of *in vitro* data against pathogens, animal PK/PD, clinical pharmacokinetics, and Monte Carlo simulations in this process. The chapter by Fadauloglou *et al* is focused on the role of post-translational modifications (PTMs) of microbial and host proteins during a successful bacterial and viral invasion in host cells. As a result, PTMs have recently emerged as novel and promising targets for the discovery of new anti-infective therapies.

Jean Michael Brunel has contributed an article on the potential of hydrazine-based agents as novel drug candidates against resistant bacteria and fungi, as well as their structure-activity relationships. The development of drugs against the second most important neglected parasitic disease, leishmaniasis, is the focus of the chapter by Roy and Mazire. They have reviewed the literature on various new therapeutic options and their current stages of development against this debilitating poor man's disease. Dengue viral hemorrhagic fever is also an important health challenge for the developing world. Leowattana *et al.* have commented on various re-purposed drugs currently in various stages of development against dengue virus infection and its various forms.

The 9th volume of this important book series comprises scholarly contributions from several leading experts to whom we are indebted. “Team Bentham” also deserves our appreciation for a job very well done. Among them, Ms. Asma Ahmed (Senior Manager Publications), and Mr. Mahmood Alam (Editorial Director) of Bentham Science Publishers have played a key role in the timely completion of the volume in hand. We sincerely hope that the efforts of authors and the production team will help readers to better understand and appreciate the importance of vigorous research and development activities currently underway against infections that cause tremendous suffering to humanity.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan

List of Contributors

- Amarnath Sharma** Clinical Pharmacology and Pharmacometrics, Janssen Research & Development LLC, New Jersey, USA
- Amit Roy** Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind Road, Pune-411007, India
- Anastasia Tomatsidou** Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Lemont, Illinois, USA
Department of Microbiology, University of Chicago, Chicago, Illinois, USA
- Dimitra Paliogianni** Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow G12 8QQ, USA
- Jean Michel Brunel** Aix Marseille University, INSERM, SSA, MCT, Marseille, France
- Mahesh N. Samtani** Clinical Pharmacology and Pharmacometrics, Janssen Research & Development LLC, New Jersey, USA
- Maria Amprazi** Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece
Department of Biology, University of Crete, Heraklion, Crete, Greece
- Pathomthep Leowattana** Tivanon Medical Clinics, 99 Tivanon Road, Muang, Nonthaburi 11000, Thailand
- Priyanka H. Mazire** Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind Road, Pune-411007, India
- Tawitthep Leowattana** Department of Medicine, Faculty of Medicine, Srinakharinwirot University, 114 Sukhumvit 23, Wattana District, Bangkok 10110, Thailand
- Vasiliki E. Fadoulglou** Department of Molecular Biology and Genetics, Democritus University of Thrace, Dragana University Campus, Alexandroupolis 68100, Evros, Greece
- Wattana Leowattana** Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Thailand

CHAPTER 1

Use of Preclinical and Early Clinical Data for Accelerating Antimicrobial Drug Development

Mahesh N. Samtani^{1*}, Amarnath Sharma¹ and Partha Nandy¹

¹ Clinical Pharmacology and Pharmacometrics, Janssen Research & Development LLC, New Jersey, USA

Abstract: Antimicrobial drug development over the last two decades suggests that the choice of dose and dosing regimen can be selected at a very early stage. This is achieved by optimizing several key factors that are properties of the drug, the bug, and the host species. Drug exposure metrics, relative to the potency of the drug, are computed during the early stages of anti-infective drug development. These metrics serve as predictors of efficacy in the animal models of infection. Drug exposure relative to its potency can be expressed using a few metrics such as AUC/MIC, T>MIC, or C_{max}/MIC . The class of drugs that the anti-infective belongs to often determines the optimal choice of the metric for a given anti-microbial (and is empirically chosen based on pre-clinical data). There are various anti-microbial drug classes available on the market. Despite a large number of drug classes, there is reasonable consensus that the PK/PD target, *i.e.* metric of relative drug exposure described above, obtained from *in vitro* and animal experiments can predict the efficacy of specific drugs in humans. The steps involved in the derivation of this crucial PK/PD metric and dosing regimen in humans are as follows: (a) First, the metric is chosen and then the magnitude of the metric is computed using *in vitro* and animal PK/PD experiments; (b) Next, drug properties such as plasma protein binding are included as correction factors for the PK/PD target; (c) Finally, the non-clinical information is combined with early clinical pharmacokinetic data to estimate which dosing regimen has the greatest probability of attaining the PK/PD metric. This methodology of computing the dosing regimen and estimating the probability of successful target attainment accounts for two key sources of variability. These are between-patient variation in clinical pharmacokinetics and the gamut of MIC values that reflect the susceptibility of pathogens to the anti-microbial drug. These sources of variability are incorporated by running Monte Carlo simulations that are population-based in nature *i.e.* they account for variability in both the pathogen and the host. These sophisticated simulations answer the critical question around the rate of target attainment for dosing regimens of the new antibiotic drug. In summary, combining *in vitro* data, animal PK/PD, early clinical pharmacokinetics, and Monte Carlo simulations expedites decision making in antimicrobial drug development. These efficiencies

* Corresponding author Mahesh N. Samtani: Clinical Pharmacology and Pharmacometrics, Janssen Research & Development LLC, New Jersey, USA; Tel.: +1-908-704-5367; E-mail: msamtani@its.jnj.com

can lead to earlier and faster entry into full development for anti-microbials and aid optimal choice of dose regimen for phase 2/3 studies.

Keywords: Antimicrobial, Drug-development, MIC, Modeling, Monte-Carlo, PK/PD, Probability, Protein-binding, Simulation, Target-attainment.

INTRODUCTION

Drug development of antimicrobials over the last 2 decades has been revolutionized by the pragmatic selection of dose and dosing regimens driven by limited but well defined and validated factors that are characteristics of the drug, the pathogen and the host [1]. A robust predictor of anti-microbial efficacy is achieving the pharmacokinetic/pharmacodynamic (PK/PD) target *i.e.* a drug exposure metric such as area under the curve (AUC) or % time above minimum inhibitory concentration (%T>MIC) or peak concentration (C_{max}) relative to the susceptibility of the organism. Despite a large number of classes of antimicrobial agents, there is increasing consensus that PK/PD targets from *in-vitro* and *in vivo*. preclinical studies are predictive of efficacy in humans [1].

One way of utilizing the PK/PD target is to examine whether the free plasma drug concentrations required for anti-microbial efficacy based on preclinical data, can be safely achieved in early human trials. The technique of examining the adequacy of different regimens to treat a myriad of pathogens is based on Monte Carlo simulation methods that allow assessment of how frequently specific doses of the new drug are expected to achieve therapeutic targets. This methodology has the potential to help with study design for subsequent phases of drug development whereby only those doses with a high probability of success are selected. The antimicrobial development process starts off with assessing antimicrobial activity of an agent *in vitro* against several different laboratory strains of microbes, followed by *in vivo* studies in appropriate animal models with microbes of interest where the right PK/PD target is established. The pathogens causing the infection stay the same across species and this allows translation of efficacy from animals to humans. The PK/PD target is also species independent because the pathogen is susceptible in any species as long as the PK exposure is achieved. The PK/PD target is both a drug and bug property since it allows tailoring the exposure relative to the pathogen's susceptibility *e.g.* exposure should increase with decreasing susceptibility [2]. This is followed by assessing pharmacokinetic characteristics of the drug in healthy human volunteers. Utilizing the totality of such information and reinforcing the knowledge surrounding susceptibility and prevalence of antibacterial strains of interest in the community, extensive Monte-Carlo simulations are undertaken to ascertain the right dose and dosing regimen for a given indication. The objectives of the Monte-Carlo analysis are to (i)

describe the population pharmacokinetic (PK) behavior of a novel anti-microbial in development by capturing the absorption and disposition properties using plasma concentrations collected during Phase 1 studies; (ii) to assess the expected performance of various doses and dosing regimens in clinically attaining PK/PD target measures associated with *in-vivo* efficacy in animal models over a range of pathogen susceptibilities using Monte Carlo simulations; and (iii) utilize the results of the Monte Carlo simulations to identify the optimal dose and dosing regimen for subsequent stages of drug development. The magnitude of the PK/PD target is generally obtained from the murine thigh infection model (but the animal model can vary depending on the infection being treated) and correction factors such as plasma protein binding are incorporated to adjust for species differences. Human PK data are usually obtained from early Phase 1 clinical studies. The pre-clinical efficacy information is then combined with the human PK data to determine which clinical dose has the highest probability of achieving the desired PK/PD target. These dosing computations and the calculation of the probability of successful target attainment explicitly account for inter-subject variability in human PK parameters during simulations, the relative natural prevalence of pathogens for target attainment, and the variability in pathogen susceptibility to allow dual individualization of pathogen and humans to the drug. The results from such exercise aids decision making for the development of novel antimicrobials. These decisions encompass the transition of a novel drug entity into full clinical development and the selection of dosing regimens for future phase II/III trials or making a “no-go” decision if PK/PD target attainment is lower than 90%.

Drug, Bug and Host Interactions: Five Critical Factors

Infections caused by multidrug-resistant bacteria are a serious threat to the general population and continue to cause significant morbidity and mortality worldwide. Application of bio-simulations that allow integration of prior information about the variability in human PK and pathogen susceptibility for assessing the likelihood of success for clinically chosen dose and dosing regimens has increased tremendously in the last 2 decades. The utility of Monte Carlo simulations for dose optimization of anti-microbials was first illustrated in 1998 to the FDA anti-infective drug products advisory committee for the antibiotic evernimicin [3]. Monte Carlo simulation allows integration of the knowledge about the PK profile of the drug and the differences in pathogen susceptibility to the drug to evaluate the expected likelihood of success of a given treatment in a particular disease during future clinical trials.

These bio-simulations are driven by five critical factors that describe the interaction between the drug, pathogen, and host [1]. These five factors include (i) the PK/PD target; (ii) distribution of pathogen susceptibility to the drug; (iii)

CHAPTER 2

Post-Translational Modifications: Host Defence Mechanism, Pathogenic Weapon, and Emerged Target of Anti-Infective Drugs

Maria Amprazi^{1,2,#}, Anastasia Tomatsidou^{3,4,#}, Dimitra Paliogianni^{5,#} and Vasiliki E. Fadouloglou^{6,*}

¹ Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Crete, Greece

² Department of Biology, University of Crete, Heraklion, Crete, Greece

³ Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Lemont, Illinois, USA

⁴ Department of Microbiology, University of Chicago, Chicago, Illinois, USA

⁵ Institute of Molecular Cell and Systems Biology, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK

⁶ Department of Molecular Biology and Genetics, Democritus University of Thrace, Dragana University Campus, Alexandroupolis 68100, Evros, Greece

Abstract: Post-translational modifications are changes introduced to proteins after their translation. They are the means to generate molecular diversity, expand protein function, control catalytic activity and trigger quick responses to a wide range of stimuli. Moreover, they regulate numerous biological processes, including pathogen invasion and host defence mechanisms. It is well established that bacteria and viruses utilize post-translational modifications on their own or their host's proteins to advance their pathogenicity. Doing so, they evade immune responses, target signaling pathways and manipulate host cytoskeleton to achieve survival, replication and propagation. Many bacterial species secrete virulence factors into the host and mediate host-pathogen interactions by inducing post-translational modifications that subvert fundamental cellular processes. Viral pathogens also utilize post translational modifications in order to overcome the host defence mechanisms and hijack its cellular machinery for their replication and propagation. For example, many coronavirus proteins are modified to achieve host invasion, evasion of immune responses and utilization of the host translational machinery. PTMs are also considered potential targets for the development of novel therapeutics from natural products with antibiotic properties, like lasso peptides and lantibiotics. The last decade, significant progress was made in understanding the mechanisms that govern PTMs and mediate regulation of

* **Corresponding author Vasiliki E. Fadouloglou:** Department of Molecular Biology and Genetics, Democritus University of Thrace, Dragana University Campus, Alexandroupolis 68100, Evros, Greece; Tel: +302551030640; E-mail: fadoulog@mbg.duth.gr

These authors have equal contribution.

protein structure and function. This urges the identification of relevant molecular targets, the design of specific drugs and the discovery of PTM-based medicine. Therefore, PTMs emerge as a highly promising field for the investigation and discovery of new therapeutics for many infectious diseases.

Keywords: ADP-ribosylation, Antimicrobial drugs, Antiviral drugs, Bacterial effector proteins, Bioengineering, Biopharmaceuticals, Coronavirus, Deamidation, Drug target, Elimination, Glycosylation, Host invasion, Innate immunity, Lantibiotics, Lipidation, Natural antimicrobial peptides, Palmitoylation, Pathogenic bacteria, RiPPs, Secretion systems, Spike protein, Thiopeptides, Ubiquitination, Vaccine design.

INTRODUCTION

After translation at the ribosome, proteins may undergo chemical changes on their amino acids. These changes are called post-translational modifications (PTMs); they display a high diversity and enumerate several hundreds of different kinds [1]. It is expected that their number will be substantially increased in the future along with the advances in technology such as the development of mass spectrometry and proteomics. PTMs can be reversible or irreversible, enzymatically or non-enzymatically catalyzed additions of diverse chemical groups ranging from small moieties to full proteins. These groups are usually added to the side chains, even though they can be linked to main chain atoms as well. Moreover, PTMs include the formation or cleavage of chemical bonds. Again, the new bonds may link side-chain or side-chain to main-chain atoms. Proteolysis is the most trivial example of chemical bond cleavage and disulfide bonds the most common, post-translational, side-chain cross links.

On the molecular level, PTMs may have multiple roles influencing the protein function, the structural stability, or the interaction network of the modified molecule. It has been shown that the addition of small, polar moieties such as hydroxyl-groups in the active site or around the active site of enzymes may increase their catalytic activity by, for example, stabilizing the transition state [2 - 4]. On the contrary, such an addition can cause the opposite effect and inactivate an enzyme if the new group of atoms is located in a place that blocks accessibility of the active site. Likewise, modification of a residue, crucial for the catalysis, will probably result in attenuation or full inactivation of the enzymatic catalysis. The formation of cross-links between different parts of a molecule or alterations to the backbone stereochemistry may increase the molecular rigidity and consequently affect structural stability and flexibility. Often, PTMs result in changes in physicochemical properties [5]. For instance, phosphorylations and deamidations usually add negative charges, Lys acylations eliminate positive

charges, hydroxylations increase the hydrophilicity, while lipidations increase the hydrophobicity of the modification site. These alterations may affect the interaction network of the protein either by introducing constraints that block existent interaction interfaces or by creating novel sites for interactions.

On the cellular level, PTMs are widely used as regulatory factors during multiple physiological processes [6]. Phosphorylation/dephosphorylation is a text-book paradigm of how a PTM may undertake a major regulatory role in signaling pathways. Likewise, histone modifications, primarily through Lys methylation and acetylation, is an essential regulatory mechanism, which controls gene-transcription activation and inactivation. Glycosylation is another well-known PTM which plays a fundamental role in molecular recognition and activation of immune response. In line with well-established knowledge, research in the last decade has discovered novel aspects of PTM biology and has demonstrated its significance and implication in more processes than it was originally expected. There are three properties that render PTMs an ideal control-switch for biological regulation. First, PTMs are usually reversible and therefore highly dynamic. Second, they do not necessarily affect the whole molecular population but just a part of it. Last, they are produced directly on site, where they are needed. This enables the cell to respond quickly and on-demand to many stimuli. We know today that this mechanism is involved in cell homeostasis, adaptation to environmental or intracellular changes including cell stress, as well as cell defence, beyond the typical glycosylation.

Not surprisingly, many pathogens, including bacteria and viruses, use PTM-based strategies to subvert eukaryotic defense and dominate their hosts [7 - 10]. Several recent studies, based on proteomics and mass spectrometry assays, indicate substantial differences in post-translationally modified proteome upon pathogen-host interactions and during infection. Pathogens can post-translationally modify their and their host's proteomes. It has been shown for example, that *Leptospira* is adapted to the host during infection by modulating both protein expression and protein PTMs, including methylation and acetylation [11]. On the other hand, the *Listeria* toxin Listeriolysin induces changes to the host proteome *via* PTMs [12]. In particular, extensive alterations of components of the host ubiquitin machinery were observed in response to the toxin. Last, a proteome comparison of virulent and attenuated *Ehrlichia* demonstrates important differences in phosphorylation and glycosylation [13]. These differences are indicative of dependence on the host interactions.

During invasion, pathogens translocate an arsenal of effectors inside the host cytosol [14 - 16]. A subset of them, in some organisms a noteworthy subset, is related with PTMs. Once within the host, these proteins can either cause

CHAPTER 3

Scope and Limitations on the Potent Antimicrobial Activities of Hydrazone Derivatives

Jean Michel Brunel^{1,*}

¹ Aix Marseille University, INSERM, SSA, MCT, Marseille, France

Abstract: Antimicrobial resistance of Gram-negative bacteria is a major concern, and no new classes of antibiotics that are effective against this type of bacteria have been discovered since the 1960s. During the last decades, multiple approaches have been developed to combat such bacterial resistance. However, the combination of antibiotic resistance mechanisms by bacteria and the limited number of effective antibiotics available, decreases the number of interventions for the treatment of current bacterial infections. The solution to emerging antibiotic resistance will likely involve new therapies or new classes of antibacterial agents. For a few years now, there was a real interest in the design and synthesis of hydrazones possessing an azomethine -NHN=CH- proton and constituting an important class of compounds for new drugs development as anticonvulsants, antidepressants, antitumoral agents. In this context, the design and antimicrobial evaluation of hydrazone derivatives have constituted one of the new strategies developed to fight bacterial resistance. As pointed out, the range of biological activities is very broad, and this review will deal exclusively with the synthesis and use of hydrazones as antimicrobial agents and will not cover the other biological properties already well depicted in literature. Thus, we will report herein the scope and limitation of such an approach providing numerous examples demonstrating structure-activity relationships and potent interesting antimicrobial activities against both fungi, Gram-positive and/or Gram-negative bacteria.

Keywords: Aldehydes, Antimicrobial agents, Antifungal activity, Antimicrobial resistance, Azomethine, Gram-positive bacteria, Gram-negative bacteria, Heterocycles, Hydrazones, Hydrazine, Ketones.


INTRODUCTION

An important interest in the design and synthesis of hydrazones possessing an azomethine -NHN=CH- proton and constituting an important class of compounds for new drugs development has recently emerged [1, 2]. Since the range of biological activities is very broad, this review will deal exclusively with the synt-

* Corresponding author Jean Michel Brunel: Aix Marseille University, INSERM, SSA, MCT, Marseille, France; Tel: (+33) 689271645; E-mail: bruneljm@yahoo.fr

thesis and use of hydrazones as antimicrobial agents, excluding the other well depicted biological properties [1 - 7].


Hydrazones, which general formula is R-NH-N=C, have been widely used and studied in organic chemistry. There are easily produced by condensation of a hydrazine (NH₂-NHR) with a ketone or an aldehyde (Scheme 1).



Scheme 1.


During numerous decades, this condensation has been the only way of detecting the presence of a ketone or an aldehyde group in a molecule. Moreover, hydrazones have also been involved in many reactions such as:

- The Bamford-Stevens reaction allowing the formation of a dual-link Z (Scheme 2) [8].



Scheme 2.

- The reaction of Shapiro [9] involves the elimination of a tosylhydrazone group and the formation of a double bond. It is noteworthy that during this reaction, the transitional carbanion can be used to graft different functional groups (Scheme 3).



Scheme 3.

Nevertheless, although these hydrazones are well known in organic chemistry, it is only recently that researchers became interested in their biological potentialities, particularly for the treatment of infectious diseases [10].


Hydrazones as Potent Antimicrobial Agents

As already mentioned, hydrazones possess a general formula R-NH-N=C. In the following part, we will discuss on the antimicrobial activity of different classes of hydrazones depending on the nature of the R group attached to the nitrogen atom.

R is a Hydrogen

In 2005, Shinge *et al.* reported the reaction of 4-acetyl-3-arylsydnone derivatives [11] with hydrazine leading to the formation of hydrazones **1** and dimers **2** in good yields and the evaluation of their antimicrobial activities against various Gram-negative bacteria and fungi (Table 1).

Table 1. Structure and antimicrobial activities of derivatives 1a-2f.



Compound	R ₁	R ₂	Diameter of Inhibition (mm)			
			<i>E. coli</i>	<i>P. pyocyanous</i>	<i>R. bataticola</i>	<i>A. niger</i>
1a	H	4-Cl	29	24	13	18
1b	H	4-Br	30	22	14	18
1c	3-CH ₃	4-CH ₃	19	18	18	21
1d	4-CH ₃	3-Cl	29	21	12	13
1e	2-OCH ₃	4-Cl	31	26	11	14
1f	4-Cl	3-F	29	23	13	16
2e	2-OCH ₃	4-Cl	18	16	11	14
2f	4-Cl	3-F	21	15	13	16

Determination of the antifungal activity of derivatives **2** led to similar results that their parent monomers **1** (Table 1, derivatives **1e-1f** and **2e-2f**) whereas weaker activities were encountered against bacteria. Moreover, compounds possessing a chloro, bromo or fluoro substituent group exhibited antibacterial activities greater than norfloxacin reference drug. Derivative **1c** with a methyl group substitution led to an increase of the antifungal activity compared to griseofulvin. Additionally, compound **1d** possessing a methyl and halogen substituent is

Current Scenario of Anti-Leishmanial Drugs and Treatment

Priyanka H. Mazire¹ and Amit Roy^{1,*}

¹ Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind Road, Pune-411007, India

Abstract: Leishmaniasis is a neglected tropical disease caused by a protozoan parasite of the genus *Leishmania*, mainly associated with the lack of community hygiene and poverty in the developing countries. Leishmaniasis can be cured but the emergence of drug resistance makes it difficult to completely eradicate the disease. Even after so many years, there is still no vaccine available against leishmaniasis. Therefore, treatment of the disease is mainly dependent on the available therapeutic drugs. However, the current chemotherapeutic drugs have several drawbacks such as high toxicity, less efficacy, high cost and emergence of drug resistance, *etc.* So, to boost the elimination of disease, development of newer therapeutic agents is imperative. As all this is very well-known, including the current anti-leishmanial drugs with their adverse effects, the authors state that the main objective of this book chapter is to present an overview of the disease, its different clinical forms and the diagnostic tools available for the detection of the disease. Natural sources such as plants and microorganisms have shown great results against *Leishmania* species over the years, indicating that they may be considered as therapeutic agents. Hereafter, potent investigational drugs obtained from the natural sources such as medicinal plants and microorganisms are also discussed in this book chapter.

Keywords: Amastigotes, Amphotericin B, Cutaneous leishmaniasis, Endophytes, Immunological tests, Kinetoplast, Leishmaniasis, Macroalgae, Miltefosine, Molecular diagnostic methods, Mucocutaneous leishmaniasis, Paromomycin, Pentamidine, Pentavalent antimonials, Post Kala-azar Dermal Leishmaniasis (PKDL), Promastigotes, Secondary metabolites, Serological diagnosis, Visceral leishmaniasis or Kala-azar.

INTRODUCTION

Leishmaniasis, a vector-borne disease caused by Trypanosomatid protozoans of the genus *Leishmania*, is classified as a neglected tropical disease having high

* Corresponding author Amit Roy: Department of Biotechnology, Savitribai Phule Pune University, Ganeshkhind Road, Pune-411007, India; Tel: 000 0000 0000; E-mail: amitavik@gmail.com

epidemiological and clinical diversity [1, 2]. The disease is endemic and more prevalent in developing countries. The disease is widely spread in about 98 countries located in South and the Central America; Southern Europe, Africa, Middle East, Central Asia and Indian subcontinent. However, more than 90% of the new cases are mainly reported in 13 countries; namely, Afghanistan, Algeria, Bangladesh, Bolivia, Brazil, Columbia, Ethiopia, India, Iran, Perú, South Sudan, Sudan and Syria [1, 3]. Approximately 700,000 to 1 million new cases occur annually. In accordance with WHO (2018), both visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) are endemic in 68 countries. VL is found to be endemic in 9 countries and CL is endemic in 21 countries. The disease is primarily associated with developing countries that have poor socio-economic status and where problems such as malnutrition, lack of resources, poor housing and sanitary conditions, *etc.* are a major concern. Environmental changes and population mobility are also considered as major risk factors (WHO, 2020) [4].

More than 20 species of *Leishmania* are known to be responsible for the disease in humans [5]. Leishmaniasis is reported to be endemic in Asia, Africa, the Mediterranean, Europe and Middle East. The five-common species of *Leishmania*, responsible for leishmaniasis are *Leishmania tropica*, *Leishmania major*, *Leishmania aethiopica*, *Leishmania infantum* and *Leishmania donovani* in Asia, Africa, Middle East and Southern Europe. While, more than six species are responsible for leishmaniasis including *Leishmania mexicana*, *Leishmania braziliensis*, *Leishmania amazonensis*, *Leishmania infantum* (*Leishmania chagasi*), *Leishmania panamensis*, *Leishmania guyanensis*, *etc.* in South and the Central America [5]. The three known clinical forms of the disease are i) cutaneous leishmaniasis (CL); ii) mucocutaneous leishmaniasis (MCL) and iii) visceral leishmaniasis (VL) [4]. In accordance with WHO, more than 95% of global VL cases were reported in 10 countries: Brazil, Ethiopia, China, India, Iraq, Nepal, Kenya, Somalia, Sudan and South Sudan in the year 2018. While, 11 countries such as Afghanistan, Algeria, Bolivia, Brazil, Colombia, the Islamic Republic of Iran, Iraq, Pakistan, Perú, the Syrian Arab Republic and Tunisia reported more than 5000 cases of CL, this together accounts for 85% of global reported CL incidence [4, 6]. India, Bangladesh and Nepal have established a collaborative association for elimination of this disease in 2005. It was renewed in 2017 and as the goal was not fulfilled, the program has been extended. The disease is still persistent with high endemicity, mainly in certain regions of India. Moreover, the incidence of VL has increased in Latin America; migration has been one of the sources for increase in number of cases. In accordance to the recent report by the Pan American Health Organization (PAHO) and the World Health Organization (WHO), incidence of VL is expanding geographically. Therefore, the VL elimination program has been extended up to 2020 to facilitate the complete eradication of the disease from the South-Asia region. In addition to

the three mentioned clinical forms of the disease, two major complications are associated with this disease. Post Kala-azar Dermal Leishmaniasis (PKDL) is a complication of VL that mainly occurs in East Africa and India. It is reported that about 5-10% of VL patients develop PKDL [6]. Moreover, HIV-VL co-infection is another complication associated with this disease. In the last few years, reported cases of *Leishmania*-HIV co-infection in endemic areas have increased. VL is considered as an opportunistic infection associated with HIV. Individuals with HIV are particularly more prone to VL infection due to suppressed immune response, leading to higher relapse and mortality rates. HIV-VL co-infection rates are high in Brazil, Ethiopia and Bihar in India. Thus, PKDL and HIV-VL co-infection are major complications of VL that affect the control of leishmaniasis (WHO, 2020).

At present, there is no effective vaccine against leishmaniasis. Therefore, treatment of leishmaniasis is entirely dependent on chemotherapeutic drugs. Pentavalent antimonials, miltefosine, paromomycin, pentamidine and liposomal amphotericin B are widely used drugs for treatment of leishmaniasis [2, 7]. However, the available drugs are toxic; have severe adverse effects and drug resistance is another problem which limits the use of these drugs [2, 7]. Therefore, the development of novel, effective, and less toxic anti-leishmanial agents having reduced side effects is the major priority. Thus, in this chapter an overview of the disease, existing treatment options, diagnostic assays currently available for leishmaniasis and the status of present anti-leishmanial drugs are highlighted.

History of Leishmaniasis

The history of leishmaniasis dates to 2,500 B.C. based on the primitive evidences reported in the ancient writings and recent molecular findings from ancient archaeological material. These reports suggest that the origin of genus *Leishmania* can be traced back in the Mesozoic era. Moreover, subsequent geographical distribution and initial evidence of the disease were reported in ancient times. First account of the infection was identified in the Middle Age, and the discovery of *Leishmania* parasites as causative agents of leishmaniasis was reported in modern times. After observing *Leishmania* organism for the first time in 1885, Russian military surgeon Peter Borovsky found out that the organism was a protozoan which was also confirmed by Wright in 1903. During this time, William Leishman and Charles Donovan described the agent responsible for VL. Leishman observed that VL-infected patients had fever and an enlarged spleen. Further, he also observed the samples from the patients under the microscope using Romanowsky method for staining and he stated that it was something he had never seen before [8]. *L. donovani* was the first identified *Leishmania* species taking its name from William Leishman (genera) and Charles Donovan (species),

CHAPTER 5

Dengue Hemorrhagic Fever: The Potential Repurposing Drugs

Wattana Leowattana^{1,*}, Pathomthep Leowattana² and Tawithep Leowattana³

¹ Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Thailand

² Tivanon Medical Clinics, 99 Tivanon Road, Muang, Nonthaburi 11000, Thailand

³ Department of Medicine, Faculty of Medicine, Srinakharinwirot University, 114 Sukhumvit 23, Wattana District, Bangkok 10110, Thailand

Abstract: Dengue is the most significant arthropod-borne viral infection of humans. More than 3.8 billion people live in endemic areas. Dengue virus infection (DVI) results in more than 500,000 hospitalizations every year, with increased threats of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) during secondary infections. In spite of the high disease burden of the dengue virus, there are no specific antiviral drugs available, and the approved vaccine is harmful in the naïve population with respect to the initiation of primary dengue infection. Several clinically approved drugs have entered human clinical trials. This review addresses the repurposing drug targets that have been investigated in DHF and DSS patients. Furthermore, their essential antiviral action and specific classes of clinically approved drugs have been clarified. These clinical trials' outcomes can enhance our understanding of the antiviral activities of these repurposing drugs to alleviate the clinical severity of dengue viral infection.

Keywords: Antiviral treatment, Balapiravir, Celgosivir, Chloroquine, Clinically approved drugs, Cromolyn, Dengue hemorrhagic fever antibiotics, Doxycycline, Ivermectin, Ketotifen, Montelukast, Repurposing drugs, Ribavirin, Rupatadine, Sofosbuvir, UV-4B.

INTRODUCTION

The Flaviviridae is a family of viruses that use humans and other mammals as natural hosts. This family is primarily spread through arthropod vectors. The common viruses of this family are yellow fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and dengue virus (DENV) [1]. DENV

* **Corresponding author Wattana Leowattana:** Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Thailand; Tel: +6623549100; E-mail: wattana.leo@mahidol.ac.th

is becoming one of the worst mosquito-borne human pathogens globally. Approximately 400 million people in more than 100 countries are infected each year, leading to 25,000 deaths [2 - 4]. *Aedes aegypti*, which is usually found in tropical areas, and *Aedes albopictus*, commonly found in subtropical areas, are the important vectors of DENV [5]. These mosquitoes are the reservoirs of DENV that could transmit it after infection. Due to the expansion of these vector species, global warming, failure to control the vectors, and urbanization mostly stimulate the drastic increase of DVI worldwide. During 2010-2020, the virus has dramatically re-emerged with significant outbreaks in Africa, South-East Asia, South America, Australia, North America, and Europe [6 - 10]. In endemic areas, most DHF patients are in the younger population, causing a high disease severity. Although DVI is almost asymptomatic and self-limiting, dengue fever (DF) could progress to severe dengue diseases [dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)]. They usually manifest as retro-orbital pain, severe headaches, muscle pain, bone pain, joint pain, nausea, vomiting, and rash. In the absence of effective prevention by a reliable safe and efficacious vaccine and specific treatment against DVI, patient management is involved in symptomatic treatment and the limitation of transmission progression. Regarding the geographical region, symptomatic patients' mortality rate varies from 1.2% to 3.5%. Hence, effective antiviral drugs to treat DVI are urgently needed [11, 12].

DENV REPLICATION

DENV is a positive-sense, single-stranded RNA virus within an envelope. There are 4 antigenically definite serotypes (DENV 1-4). The first step in infection is the virus particle interaction with the host cell receptors with envelope (E) glycoprotein. There are several host cell receptors such as glycosaminoglycans (GAGs), dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN), and T-cell immunoglobulin-mucin domain (TIM). After that, the virus penetrates the host cells by endocytosis [13]. The conformational modifications in the E glycoprotein are induced by low pH within the endosomal vesicle causing the fusion of membrane, and the nucleocapsid is released into the cytoplasm. Moreover, the viral RNA is translated into 1 polyprotein and then is spliced into three structural proteins; capsid (C), membrane (M), envelop (E), and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The NS proteins utilize lipid metabolism in that cell and produce a re-organization of the endoplasmic reticulum (ER) membrane where viral RNA is replicated inside. Many enzymes in cells, such as kinases and α -glucosidases, serve to replicate RNA, translation, and folding of that protein. Several copies of the C protein package newly initiated genomic RNA and the nucleocapsid and then bud into the lumen of ER to create an enveloped immature virion. Hence, virions are transported *via* the secretory pathway where the E and M proteins

encounter post-translational adaptations and conformational changes, comprising the breakdown of precursor M to its mature form by protease furin of the host cell. Progeny virus release occurs through exocytosis and can infect another cell [14]. Molecular study of DENV life cycle and the interaction between virus and host have warranted finding out the small-molecule and peptide antagonists against the interaction of virus and the host cell, the processing of RNA, the genome replication, and the assembly and budding of the mature virus [15 - 17].

The key challenge to dengue therapeutics' success is the rapid decrease in viremia of the patient during a febrile phase, especially in secondary DVI. Hence, the ideal drug that could inhibit DENV should be rapid, active against the four DENV serotypes, possess a good safety window and minimal drug interaction. Many drug candidates have been developed which inhibit either a host or viral protein essential for entry, translation of polyprotein by a proteolytic process, RNA replication, the packaging of the viral genome, and the release of the virion from affected cells. However, all of the candidates have not proved to be better than the placebo in a clinical trial. The discrepancy between pre-clinical and clinical outcomes is the fundamental factor of the study designed. The most common factors included the indefinite and broad spectrum clinical manifestations, the lack of animal models, the limitation of a biological parameter that correlates with clinical outcomes, and the limited financial support for the clinical trials.

Drug repositioning or repurposing can be taken into account as a primary objective and is urgently needed. The repurposing drugs may be authorized or currently used against several clinical situations, or they can be alternatives that have not been successful in any stage of the clinical studies for different purposes. Notably, repurposing drugs are the revelation of new investigations for authorized or unsuccessful agents. The drug repurposing strategy's significance is a quicker and more secure pathway to create new drugs for DHF and DSS management for which a specific treatment is still unavailable. Drug repurposing provides the potentiality to decrease duration and hazards intrinsic to the process of discovery of any drug and urgently advance a candidate drug to the final stage of development [18 - 20]. Moreover, drug repurposing provides an opportunity to develop multi-target drugs able to interfere with several pathways concerned in the pathophysiology of the specific diseases. Multi-target drugs have many advantages such as a synergistic effect, acting on different targets, simplified pharmacokinetics and pharmacodynamics profile, good compliance, and a lower opportunity of drug interferences [21, 22].

SUBJECT INDEX

A

- Abdominal cramps 55
 ACE2 receptor 68
 Acetylation 27, 32
 levels 32
 Acetyltransferase 35, 39, 85
 Acid(s) 56, 57, 69, 80, 81, 82, 131, 142, 150,
 167, 170
 anacardic 150
 carboxylic 142
 dehydroamino 80, 81, 82
 fatty 69, 170
 nonulosonate sugar legionaminic 57
 nucleic 167
 oxalic 131
 pseudaminic 56
 transferring glutamic 81
Acinetobacter baumannii 141
 Active transport system 170, 176
 Activity 13, 35, 37, 38, 39, 40, 43, 44, 45, 47,
 48, 49, 50, 58, 59, 60, 61, 62, 69, 70, 80,
 84, 85, 129, 130, 139, 140, 165, 173,
 177, 187, 196
 acyltransferase 44
 antituberculosis 130
 antiviral 139, 187
 cytokine 196
 deamidase 44, 48
 enzymatic 35, 37, 38, 39, 45, 50, 85
 fungicidal 173
 glucosyltransferase 60
 glycosyltransferase 58, 59
 haemolytic 140
 hemopoietic 165
 leishmanicidal 177
 phosphatase 40
 proteolytic 80
 synergistic 47
 Adaptive immunity 28, 30, 32, 84, 85
 ADP-ribosylation 26, 28, 44, 46, 47, 63, 65
 factor 44
 signaling 46
 transferases 46
 Akt protein kinase 52
 Amastigotes 156, 160, 161, 162, 163, 165,
 167, 178, 179
 axenic 178
 intracellular 179
 Amino acid protein synthesis 192
 Amphotericin B (AmB) 156, 158, 168, 169,
 170, 171, 172, 173, 174, 176
 Andean sickness 159
 Anemia 163, 165
 Antibody-dependent enhancement (ADE) 195
 Antifungal activities 123, 125, 133, 135, 140,
 143, 147
 Anti-leishmanial 167, 177, 178, 179, 180
 activity 177, 178, 179, 180
 medicines 167
 Antimicrobial activities 77, 79, 83, 86, 125,
 128, 132, 134, 135, 136, 137, 138, 139,
 146, 147, 148, 149, 150
 broad-spectrum 137
 of hydrazones 134, 135, 137
 of quinoline derivatives 132
 Antiviral drugs 26, 86, 187, 191, 193
 broad-spectrum 193
 Apoptosis 32, 40, 48, 61
 chemotherapeutic-induced 40
 Assay 167, 193, 198
 enzyme-linked immunosorbent 167
 protein-protein binding 198
 Assembly 56, 80
 flagellar filament 56
 ribosomal 80
 ATPase activity 197
 ATP-dependent lactam synthase 79
 Autoproteolysis 48

B

Bacillus subtilis 75

Subject Index

Bacteria 27, 28, 47, 52, 54, 55, 74, 84, 85, 123, 125, 126, 130, 131, 134, 192
dissemination 47
Bacterial 35, 42, 46, 48, 50, 52, 58, 85
cholera 46
E3-ligases 50
pathogenicity factor 42
proteins 35, 52, 85
toxins 48, 58
Bacterial replication 52, 137
intracellular 52
Bacterial surface 58, 71
polysaccharides 71
Proteins 58
Biosynthesis 57, 77, 78, 79, 80, 81, 82, 83, 86
gene clusters (BGCs) 77, 80, 81
glutamylation enzymes 81
lanthipeptide 83
lantibiotic 82
lasso peptide 79
thiopeptide 80

C

Campylobacter jejuni 55
Cell 27, 60, 84
free system 60
homeostasis 27, 84
Cell death 38, 60, 61, 76, 193
necrotic 38
cGAS signalling pathway 32
Chronic hepatitis C (CHC) 191, 192, 194
Cif proteins target Gln40 49
Cleavage 26, 31, 32, 59, 63, 65, 69
auto-proteolytic 59
chemical bond 26
proteolytic 31, 65, 69
CL 159, 165
lack specificity 165
lesions 159
Clostridium 57
botulinum 57
difficile 57
Combination therapy 169, 172, 173
Common pathogenic bacteria 73
Components 27, 30, 32, 50, 59
antiviral signalling 32
Concentrations 5, 13, 128, 145, 148, 149, 150, 192, 193, 194, 198, 199
cytokine 194

Frontiers in Anti-Infective Drug Discovery, Vol. 9 209

cytotoxic 192
lower liver enzyme 199
sustained 5
Control 25, 62
catalytic activity 25
host proteins 62
Core peptide 77, 79, 81, 86, 87
released 79
Coronavirinae 63
subfamily 63
Coronavirus 25, 26, 28, 62, 63, 65, 66, 67, 68, 69, 70, 85, 86
human pathogenic 66
infection 67
proteins 25, 65, 68, 69, 70, 85, 86
Cutaneous leishmaniasis (CL) 8, 9, 10, 127, 128, 129, 156, 157, 159, 162, 164, 165, 168, 169, 173
Cyclic GMP/AMP synthase 30
Cycloaddition reaction 81
Cyclodehydration reaction 81
Cytokine(s) 30, 45, 55, 79, 190, 192, 194, 196
inflammatory 30, 45
pro-inflammatory 55
protease activity 79
transcription of 192
Cytotoxic Necrotizing Factors (CNFs) 47, 48

D

Damage 31, 39, 165, 199, 200
minimal tissue 199
sensors 31
vascular 200
Danger-associated molecular patterns (DAMPs) 30
Deamidases 48, 49, 50, 53
Death 61, 62
domain (DDs) 61, 62
inducing signaling complex (DISC) 61
Degradation 30, 33, 40, 50, 51, 52, 70
autophagic 51
proteasomal 52
proteasome 33, 51, 52
proteosomal 70
Dehydrogenases 81, 167
Demyristoylase 44
Dengue 187, 188, 189, 193, 194, 195, 199, 201
disease severity 201

fever (DF) 188, 194
 serotypes 193
 shock syndrome (DSS) 187, 188, 193, 195, 199
 therapeutics 189
 Dengue virus 187, 188, 193, 195, 196, 198, 199, 201
 infection (DVI) 187, 188, 193, 195, 196, 198, 199, 201
 DENV2 polymerase 191
 Desumoylases 39
 Diagnosis 165, 166, 167
 confirmed 165
 Diarrhea 55, 57, 61, 164, 173
 antibiotic-associated 57
 infantile 61
 non-inflammatory 55
 Disease 26, 28, 62, 72, 73, 74, 87, 124, 156, 157, 158, 159, 162, 163, 164, 165, 166, 167, 180, 189, 191
 asymptomatic 166
 infectious 26, 28, 62, 72, 87, 124
 metabolic 74
 neglected tropical 156, 180
 progression 74
 treatment 167
 Downstream signalling molecules 32
 Doxycycline's anti-dengue activity 193
 Drug development 1, 16, 17, 180
 accelerating antibiotic 16
 anti-infective 1
 process 180
 program 17
 Drug exposure 1, 4, 5, 9, 11, 12
 anticipated 9
 relative 1
 Drugs 1, 2, 3, 4, 5, 7, 8, 13, 15, 17, 18, 67, 74, 125, 156, 158, 168, 169, 170, 173, 174, 175, 176, 180, 192, 196, 197, 198, 201
 antibacterial 74
 anti-inflammatory 196
 antileishmanial 170
 anti-microbial 1
 anti-parasitic 196, 197, 198
 chemotherapeutic 156, 158
 leishmanial 176
 norfloxacin reference 125
 phospholipid 173
 synergistic 192
 targeted therapeutics 201

E

Effectors 37, 38, 39, 40, 41, 42, 43, 45, 46, 50, 51, 52, 59, 60, 61, 74
 bifunctional 46
 glycosyltransferase 60
 pathogenic 42
 pseudotuberculosis 74
 translocated 42
 Effects 17, 72, 173, 176, 179, 189
 antimicrobial 17
 gastrointestinal 173, 176
 high cytotoxic 179
 synergistic 189
 therapeutic 72
 Efficacy 1, 2, 8, 13, 156, 169, 170, 172, 174, 175, 180
 anti-microbial 2
 Elimination 26, 76, 84, 124, 156, 157
 bacterial 76
 phosphate 84
 Emergence 18
 suppress resistance 18
 Endocarditis 7
 Endocytosis 59, 188, 196
 clathrin-mediated 59
 endosome-mediated 196
Enterococcus faecalis 7
 Enzymatic 78, 79
 cycloaddition 78
 inhibitory activity 79
 Enzymes 26, 34, 50, 51, 54, 64, 70, 76, 79, 81, 82, 83, 86, 87
 angiotensin-converting 64
 biosynthetic 79
 de-ISGylating 70
 EPEC pathogenesis 61
 Epidermidis 126
 Estrogen cancer 72
 Eukaryotic 28, 33, 43, 44, 50, 53, 73, 85
 proteins 28, 43, 44, 50, 73, 85
 regulatory processes 33
 transferases 85
 ubiquitination systems 53

F

Factor inhibiting HIF (FIH) 42

Subject Index

Factors 2, 3, 5, 33, 43, 47, 48, 50, 59, 80, 167, 201
antimicrobial 33
elongation initiation 47, 48
eukaryotic elongation 59
guanine nucleotide exchange 43
lethal 48
nuclear transport 167
targeting bacterial elongation 80
targeting elongation 80
tumor necrosis 50
validated 2
FAS-associated death domain protein 61
Fatal cardiac arrhythmias 175
Fatty acid-oxidation 176
Fever 158, 163, 164, 170, 174, 188, 190, 191, 194
hemorrhagic 188, 191
prolonged 164
Fibroblasts 160, 161
Flagellar proteins 56, 85
bacterial 85
glycosylated 56
Flagellins 55, 56, 57, 58
glycosylated 56
non-glycosylated 57, 58
Focal adhesion kinase (FAK) 40
Food and drug administration (FDA) 3, 191
Function 32, 37, 38, 39, 40, 44, 45, 47, 48, 50, 51, 52, 63, 64, 72, 73, 80, 140
catalytic 52
cellular 47
drug-transporter 72
enzymatic 45
hydrazone 140
inhibitory 80

G

Gastrointestinal pathogen 61
Gel electrophoresis, pH-dependent 166
Gelsolin actin-remodelling protein 37
Genes, pglB 58
Glucohydrolase 60
Glucose phosphate isomerase (GPI) 167
Glutamylase 81
Glycans 31, 33, 56, 57, 58, 65, 66
complex 65
flagellin 57
free 58

Frontiers in Anti-Infective Drug Discovery, Vol. 9 211

oligomannose-type 66
seven-residue 58
Glycolysis 170, 176
Glycoproteins 56, 64, 66, 68, 188, 193
viral 68
Glycosidic linkage 46, 85
Glycosylation 26, 27, 28, 54, 55, 56, 57, 58, 59, 60, 63, 65, 67, 71, 85
blocking histone 60
changing FlaA 56
flagellar 55
flagellin 58
homogeneity 56
machinery 71
modification 67
GTPase 33, 35, 37, 46, 59, 60, 80
-activating proteins (GAPs) 46, 59
-associated centre (GAC) 80
domain 37, 60
-inhibiting protein 35
-mediated signalling 33
GTP-hydrolysis 48
Guillain-Barré syndrome 56

H

Hank-type eukaryotic protein kinase 37
Hantavirus infection 191
Hantzs reaction 135
HCV 190, 191, 193
infection 191, 193
treatment 190
Headaches, severe 188
Heat shock protein 166
HeLa cells 45
Hepatitis 73, 190, 191
C virus (HCV) 73, 190, 191
chronic 191
Hepatomegaly 165
Hepatosplenomegaly 163
HIV infection 194
Host enzyme-inhibitory activity 193
Host 25, 28, 35, 42, 43, 50, 52, 55, 60
geranylgeranyl transferase 43
pathogen interactions 25, 28, 42, 55
protein synthesis inhibition 60
signaling pathways 35
translational machinery 25
ubiquitination network 50, 52
Host cell 48, 51, 61, 62, 188

- cycle progression 48
- functions 61
- lipid metabolism 51
- proteins 62
- receptors 188
- Host-mediated 39, 42, 46
 - effector modifications 46
 - post translational lipidations 42
 - post-translational modifications 39
- Human immunodeficiency virus (HIV) 62, 79, 158, 191
- Hydrazone derivatives 129, 134, 139, 146, 148
 - clubbed 146
 - first cholesteryl 139
 - imidazole 148
 - quinolyl 129
 - steroid 134
 - synthesized 142
- Hydrazones 123, 124, 125, 128, 134, 135, 137, 138, 139, 140, 145, 147, 149, 150
 - design and synthesis of 123, 150
 - modified pyridine-based 147
 - novel cyanoacetyl 149
- Hyperplasia 165

I

- Immune-mediated disorders 55
- Immune responses 25, 27, 30, 33, 35, 38, 39, 44, 45, 50, 55, 57, 58, 59, 61, 65, 66, 70, 73, 85, 158, 178
 - adaptive 55
 - humoral 65, 66, 178
 - innate 35, 39, 50, 58, 70
 - suppressed 158
- Immune system 8, 12, 17, 29, 35, 55, 67, 76, 86, 167
 - innate 67
- Indirect fluorescent antibody (IFA) 167
- Infection 1, 2, 3, 5, 7, 8, 12, 13, 27, 28, 30, 38, 46, 50, 52, 55, 56, 57, 74, 75, 76, 81, 123, 158, 162, 163, 165, 167, 175, 187, 188, 191, 199
 - acute dengue 199
 - bacterial 50, 74, 76, 123
 - body site animal 7
 - botulinum 57
 - concomitant 167
 - dengue virus 187

- difficile 75, 81
- fatal 56
- fungal 165
- leishmanial 175
- life-threatening 5, 12
- opportunistic 158
- parasitic 162
- pathogenic 30
- primary dengue 187
- progressive 163
- skin structure 7
- somni 76
- streptococcal 165
- Infectious bronchitis virus (IBV) 65, 67, 69
- Inflammasome 38, 55
- Inhibiting Leishmania infection 173
- Inhibition 35, 37, 38, 78, 130, 131, 137, 139, 147, 148, 149, 150, 176, 177, 179, 193
 - demonstrating concentration-dependent 193
 - steric 78
- Inhibition target protein 72
- IRF pathways 30
- Iron superoxide dismutase 167

J

- Japanese encephalitis virus (JEV) 187

K

- Kinase 30, 36, 37, 40, 45, 85, 188
 - extracellular signal-regulated protein 45
 - mitogen-activated protein 30
- Kinetoplast 156, 160
 - terminal 160
- Kinetoplast DNA 160, 167
- Kinetoplastids 176

L

- Lactobacillus* 82, 83
 - bulgaricus* 82
 - lactis* 83
- Lactococcus lactis* 78, 82
- Lan synthases 84
- Leader peptide (LP) 77, 79, 81, 82, 83, 86
- Leishmania* 157, 159, 176
 - aethiopica* 157
 - amastigotes* 176

Subject Index

amazonensis 157
chagasi 157
donovani 157, 159
Leishmaniasis 156, 157, 158, 159, 161, 162, 163, 164, 165, 167, 169, 175, 176, 179, 180
 mucosal 163, 164
 treatment of 158, 169, 175, 179, 180
 HIV co-infection 169
Lesions 61, 159, 162, 163, 164, 168, 178
 cutaneous 159, 164
 human PKDL 163
 initial skin 164
 metastatic 163, 164
Leucopenia 163, 165
Ligases 34, 49, 76
 cullin-RING E3 49
 eukaryotic Ub 76
 single-subunit E3 34
Liposomal amphotericin 158, 168, 169, 170, 173
Liver function tests (LFTs) 174
Localized cutaneous leishmaniasis (LCL) 160

M

Macrocyclization reaction 81
Macrophage phagolysosome 161
Mannose phosphate isomerase (MPI) 167
MaoC family dehydratase 167
MAPKs, modifies 45
Marburg infections 191
Melioidosis 48
Membrane 38, 44, 85, 175, 193
 celgosivir crosses cell 193
 eukaryotic 38
 mitochondrial 175
 pathogen-containing vacuole 85
 phagosome 44
Membrane lipids 42
Methicillin-resistant *Staphylococcus aureus* (MRSA) 18
Micrococcus luteus 79
Miller fisher syndrome 56
Minimum inhibitory concentration (MIC) 1, 2, 4, 5, 9, 11, 16, 20, 126, 129, 133, 134, 140, 141, 145
Mitogen-activated protein kinases (MAPKs) 30, 39, 45

Frontiers in Anti-Infective Drug Discovery, Vol. 9 213

Modifications 25, 26, 27, 28, 33, 35, 39, 42, 43, 44, 45, 46, 47, 80, 81, 188
 conformational 188
 histone 27
 nonenzymatic 47
 post translational 25
Molecular diagnostic 156, 166
 methods 156
 tools 166
Monocytosis 165
Monte-Carlo 2, 6, 11, 13, 16, 17, 18
 analysis 2
 approach 13, 17
 computations 6
 methods 16
 optimization 11
 simulation methods 2
Mucocutaneous leishmaniasis (MCL) 156, 157, 159, 160, 163, 164, 165, 168, 174
Multilocus enzyme electrophoresis (MLEE) 166
Multiple facets of glycosylation 54

N

Natural 14, 76
 antimicrobial peptides aid search 76
 frequency of occurrence of pathogens in CSSI 14
Neisseria meningitidis 58
Neutropenia 165
NF- κ B activation 61, 62
Non 54, 83, 197
 canonical ubiquitinase 54
 competitive antagonist 197
 enzymatic hydrolysis 83
Nuclear import mechanisms 198
Nucleic acid sequence-based amplification (NASBA) 167
Nucleocapsid 63, 64, 65, 188
 symmetric 63
Nucleotidyl cyclase 39

O

Osteomyelitis 7
Ototoxicity 174
Oxidoreductase 83

P

- Pain 188, 197
 - bone 188
 - joint 188
 - muscle 188
 - retro-orbital 188
- Pan American health organization (PAHO) 157
- Pancreatitis 170, 175
- Parapsilosis 141
- Parasites 156, 159, 160, 164, 165, 166, 167, 170, 176, 179, 192, 197
 - microscopic observation of 166
 - protozoan 156
 - visualize 165
- Paromomycin 156, 158, 169, 170, 172, 173, 174
 - intramuscular 173
- Pasteurella multocida toxin (PMT) 48
- Pathogen-associated molecular patterns (PAMPs) 30
- Pathogenic invasion 29
- Pathogenicity 25, 28, 45, 46, 47, 48, 53, 54, 55, 64, 86
 - bacterial 46, 47, 54, 55
 - infectious 28, 86
 - microbial 28
- Pathogen 1, 3, 4, 5, 6, 7, 11, 13, 15, 28, 74, 79
 - replication 74
 - RNA polymerase 79
 - susceptibility 1, 3, 4, 5, 6, 7, 11, 13, 15
 - virulence 28
- Pathways 30, 33, 34, 58, 65, 72, 189, 196
 - cellular 34
 - immune response signalling 30
 - proinflammatory cytokine 196
- Pattern-recognition receptors (PRRs) 30
- PCR 166
 - assays 166
 - method 166
 - restriction fragment length polymorphism 166
- Peptidyl-prolyl cis-trans isomerase 167
- Peripheral blood 159, 190
 - lymphocytes 159
 - mononuclear cells (PBMC) 190
- Phagocytic cells 35, 160
 - mononuclear 160
- Phagocytosis 35, 37, 38, 47
- Pharmacodynamics profile 189
- Phosphatases 45, 52, 85, 174
 - elevated alkaline 174
 - phosphoinositide 52
- Phosphorylation-dependent protein-protein interactions 73
- Phosphoryl transfer mechanism 45
- Phosphothreonine lyase activity 45
- Photorhabdus asymbiotica multifunctional 35
- Plasmacytoid 196
- Plasma 1, 3, 4
 - drug concentrations 4
 - protein binding 1, 3
- Platelet-activating factor (PAF) 199, 200
- PMT arrests heterotrimeric 48
- Pneumonia 7, 13, 47, 57
 - associated 13
 - lethal necrotizing 57
- Pneumoniae 75, 127, 130
- Pneumophila phagocytosis 75
- Polymerase chain reaction (PCR) 166, 167
- Post Kala-azar Dermal Leishmaniasis (PKDL) 156, 158, 163, 165, 169
- Post-translational 25, 26, 27, 28, 29, 30, 34, 35, 39, 44, 62, 64, 65, 70, 71, 72, 73, 77, 84, 86, 87, 189
 - adaptations 189
 - de-lipidation 44
 - modifications (PTMs) 25, 26, 27, 28, 29, 30, 34, 35, 39, 62, 64, 65, 70, 71, 72, 73, 77, 84, 86, 87
- Processes 6, 11, 16, 27, 28, 33, 37, 55, 58, 72, 73, 76, 81, 170, 175, 176, 189
 - actin-polymerization 37
 - bioenergetics 176
 - computation 6
 - polymerization 37
 - proteolytic 189
 - respiration 175
 - transcription 170, 176
- Production 30, 32, 33, 70, 71, 79, 85, 87
 - cost-effective 71
 - mass 87
- Proinflammatory cytokines 31, 32, 70, 196
 - downregulates 196
- Prokaryotic expression systems 71
- Properties 1, 3, 4, 8, 26, 27, 64, 70, 72, 79, 84, 85, 87, 126, 192
 - antifungal 126
 - disposition 3

Subject Index

physicochemical 26
physiochemical 64
physiological 84
therapeutic 70, 72
unique PTM 85
Protease 39, 48, 59, 64, 69, 85, 86, 198
 cleavage 64
 cysteine 39, 48
 domain 59
Proteasome degradation levels 49
Proteins 5, 8, 12, 27, 32, 33, 35, 39, 42, 43,
 44, 47, 48, 51, 53, 54, 55, 56, 60, 62, 63,
 64, 65, 66, 67, 68, 69, 70, 71, 73, 76
 AMPylation 76
 binding 5, 8, 12, 68
 dimerization 65
 expression 27
 flagellin 55, 56
 glycosylation 54
 inhibition 70
 monomer 66
 palmitoylated 68
 polyubiquitinated 42
 prokaryotic 71
 regulatory 32, 33, 60
 therapeutic 70
 transmembrane 64
Protein-protein interaction 42, 72, 73
 modulator 42
Proteinuria 174
Proteolysis 26, 78
Proteolysis-targeting chimeras (PROTACs) 72
PRR-dependent inflammatory responses 32
Pseudomonas aeruginosa 7, 13, 39
 exoenzymes 39
PTMs 69, 85
 of host proteins 69
 on eukaryotic proteins 85
Pyelonephritis 7

R

Rab GTPases 62
RAF-1 kinase pathway 73
Receptors 30, 32, 50, 55, 61, 64, 67, 173, 199
 cytoplasmic dsRNA 32
 leukotriene 199
Red blood cells (RBC) 164, 165
Reduced viral replication 196, 198

Frontiers in Anti-Infective Drug Discovery, Vol. 9 215

Residues 34, 35, 44, 46, 47, 48, 53, 56, 57, 59,
 60, 61, 78, 79, 82
 amino-terminal 44
 lysine 34
Resistance 17, 18, 74, 123, 165, 167, 175
 antibacterial 17
 bacterial 18, 123
Respiratory 62, 191
 syncytial virus (RSV) 191
 syndrome coronavirus 62
Restriction fragment length polymorphism
 (RFLP) 166
RiPP 81, 82
 biosynthesis 82
 biosynthetic pathway 82
 recognition element (RRE) 81
RNA 65, 69, 167, 188, 189, 191, 192, 195
 aminoacyl transfer 192
 dependent RNA polymerase 195
 exon-derived 167
 initiated genomic 188
 polymerase 191
 replication 189
 ribosomal messenger 192
 viral 69, 188, 192
RNA genome 63, 65
 viral 63

S

Salmonella infection 45, 62
Salmonella typhimurium 43
SARS-CoV 62, 63, 65, 66, 67, 68, 69, 70
Seasonal 62, 199
 allergies 199
 epidemics 62
Secondary metabolites 80, 156, 177
Secretion, inflammatory cytokine 62
Ser/Thr dehydration reaction 82
Signaling 38, 59, 61
 blocking Rho-dependent 59
 contact-dependent 38
 death-inducing 61
Signalling pathway 30, 32
 downstream 30
Signal 38, 166
 transduction mechanism 38
 strand conformation polymorphisms
 (SSCP) 166
Skin 6, 7, 159, 162, 163, 164, 165, 198

- complicated 7
 - darkened 164
 - facial 162
 - infection 6, 198
 - lesions 159, 162, 164, 165
 - pigmentation 162
 - thickening 162, 164
 - Sofosbuvir 187, 191, 195
 - evaluated 191
 - triphosphate 191
 - Species 2, 5, 8, 11, 13, 16, 17, 25, 28, 147, 55, 58, 85, 157, 158, 160, 166, 167, 177, 178
 - azole-resistant fungal 147
 - bacterial 13, 17, 25, 55, 58, 85
 - infectious 28
 - Splenomegaly 159, 164, 193
 - reduced 193
 - Stability 33, 54, 70, 82, 83, 86, 178
 - metabolic 82
 - proteolytic 83
 - Staphylococcus* 79, 83, 141
 - aureus* 79, 141
 - epidermis* 83
 - gallinarum* 83
 - Steric interactions 77
 - Strategy 46, 52, 73
 - antiviral 73
 - novel therapeutic 46
 - Streptomyces* 83, 170, 174, 197
 - avermectinius* 197
 - cinnamoneus* 83
 - nodosus* 170
 - rimosus* 174
 - Stress 33, 58, 68, 193
 - fiber formation 33
 - osmotic 58
 - oxidative 68
 - Structures of hydrazone derivatives 140
 - Subvert eukaryotic defence 85
 - Survival 25, 28, 33, 35, 43, 52, 62, 85, 194
 - bacterial 52, 62
 - intracellular 35, 52
 - microbial 28
 - viral 85
 - Synthesis 65, 123, 126, 133, 134, 135, 137, 139, 140, 142, 143, 145, 146, 147, 148, 149, 150, 170, 174, 198
 - coronavirus RNA 65
 - cytokine 198
 - of phosphatidylcholine 170, 174
 - stereoselective 149
- ## T
- Target 25, 74, 76, 79
 - pathogenic bacteria 76
 - RNA polymerases 79
 - signaling pathways 25
 - virulence factors 74
 - TCS signal transduction 75
 - Teratogenicity 170, 173
 - Therapeutic(s) 25, 28, 77, 86, 156
 - agents 156
 - drugs 156
 - novel 25, 76, 77
 - protein-based 86
 - Therapy 18, 167, 168, 194, 197
 - delayed 194
 - direct anti-viral 18
 - early antiviral 194
 - lice 197
 - long-term 18
 - Thermo-labile RNA structure 47
 - Thermotherapy 168
 - Thif-Ocin-like protein 81
 - TNF α -induced NF- κ B activation 70
 - Toll-like receptors (TLRs) 30, 31, 32
 - TonB pathway 79
 - Toxicity 76, 87, 169, 171, 172, 175, 176, 179
 - cellular 76
 - reduced 76, 171
 - renal 176
 - Toxic shock, limiting 76
 - Toxin(s) 27, 33, 35, 46, 48, 58, 59, 75
 - binding agents 75
 - diphtheria 46
 - hemorrhagic 59
 - secreted 75
 - virulence-related PaTox 35
 - Trafficking 60, 67
 - endocytic secretory 60
 - eukaryotic vesicle 60
 - Transcription factors pauses host protein synthesis 48
 - Treatment 76, 81, 123, 124, 156, 167, 168, 169, 172, 173, 174, 175, 176, 178, 188, 189, 190, 191, 192, 194, 196, 199
 - acne 81
 - cost-effective 176

Subject Index

delayed 190, 194
prophylactic 76
rheumatoid arthritis 196
rupatadine 199
symptomatic 188
therapeutic 76
Tumor necrosis factor (TNF) 50

U

Ubiquitin 48, 49, 53, 70
 degradation 70
 transglutaminases 49, 53
 ubiquitin-like protein signaling pathways 48
Ubiquitin ligases 40, 42, 43, 70, 72, 76
 box E3 42
 cellular E3 70
Ulcerative colitis 199
Ultrasonic irradiation 136
Unfolded protein response (UPR) 193

V

Vaccines 62, 70, 71, 86, 156, 158, 172
 effective 86, 158
Vacuolar membrane integrity 51
Vascular leakage 198, 199, 200
 increased 198
 Reduction of 200
Vascular permeability syndrome, severe 194
Vasculopathy 200
Vero cells 192, 198
 of doxycycline 192
Versatile Tyr-phosphatase 38
Vibrio parahaemolyticus 46, 48
Viral 68, 79, 189, 190, 191, 192, 194, 198
 eradication 198
 genome 189
 genome transcription/replication 68
 hemorrhagic fevers 191
 infection-induced cytokine reaction 190
 load 192, 194
 reverse transcriptase 79
 RNA synthesis inhibitor 191
Viral proteins 62, 86, 189, 193
 modified 62
Virion 63, 64, 65, 67, 188, 189
 assembly 63, 64, 67

Frontiers in Anti-Infective Drug Discovery, Vol. 9 217

enveloped immature 188
Virulence 28, 34, 40, 46, 47, 51, 52, 56, 57,
 59, 62, 70, 72, 74, 75
 bacterial 40, 47, 62
 blockers 74, 75
 reduced 56
 systemic 51
Virus 62, 65, 66, 70, 73, 85, 86, 187, 188, 189,
 191, 196
 hemorrhagic fever 73
 human immunodeficiency 62
 infectious bronchitis 65
 influenza 62
 non-glycosylated transmissible
 gastroenteritis 65
 respiratory syncytial 191
 single-stranded RNA 188
 yellow fever 187
Visceral leishmaniasis (VL) 156, 157, 158,
 162, 163, 164, 165, 166, 167, 168, 169,
 170, 172, 173, 180
VL elimination program 157

W

West Nile virus (WNV) 187
WHO guidelines 167, 169, 174, 175, 176
Whole-cell-killed bacteria 71
World Health Organization (WHO) 157, 158,
 160, 162, 163, 180

Y

Yellow fever virus (YFV) 187
Yersinia 35
 enterocolitica 35
 pestis 35

Z

Zika virus 73



PROF. DR. ATTA-UR-RAHMAN, FRS

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.



PROF. DR. M. IQBAL CHOUDHARY

Dr. M. Iqbal Choudhary is a Professor of Organic/Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research) and Coordinator General of COMSTECH (OIC Ministerial Committee). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 1000 research papers and chapters in top international science journals of the West as well as 27 US patents (H-index: 68 & Citations: 27,500). He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University of Rhode Island (Rhode Island), and other top Universities.